AbCellera Biologics (ABCL) Liabilities and Shareholders Equity (2020 - 2026)

AbCellera Biologics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 2.76% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 billion (down 1.6% YoY) and the FY2025 annual result came in at $1.4 billion, changed 0.26% from the prior year.
• Liabilities and Shareholders Equity was $1.3 billion for Q1 2026 at AbCellera Biologics, down from $1.4 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q2 2022 and bottomed at $1.3 billion in Q1 2026.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 41.09% — and 2024, when it declined 8.57%.
• AbCellera Biologics' Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then decreased by 3.43% to $1.5 billion in 2023, then retreated by 8.57% to $1.4 billion in 2024, then dropped by 0.26% to $1.4 billion in 2025, then declined by 3.67% to $1.3 billion in 2026.
• Business Quant data shows ABCL's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.